(RPTX) – Company Press Releases
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
-
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
-
Repare Therapeutics to Regain Global Rights to Camonsertib
-
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
-
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
-
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
-
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
-
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
-
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
-
VedaBio Unveils World Class Scientific Advisory Board
-
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
-
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets a
-
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
-
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
-
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
-
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
-
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
-
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
-
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
-
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
-
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
-
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
-
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
-
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
-
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
-
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
-
Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
-
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
-
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
-
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
Back to RPTX Stock Lookup
